Synairgen Share Discussion Threads

[investordave] 30/10/2020 08:54

And hopefully a long, long way to go. We're barely at the placing price yet.

[daveboy1] 30/10/2020 08:52

Hope you're right, 007.

[nortic 007] 30/10/2020 08:51

This move feels like it my have legs. The iceberg seller seems to have abated!!

[wetdream] 30/10/2020 08:19

Posted by ‘Ducati2’ on LSE:
——————————-

We are in the FAST LANE!



The U.K. government is conferring urgent public health research status on select programs, which offers a kind of fast-lane to the most promising programs. Synairgen’s inhaled formulation of interferon-beta, SNG-001, recently received that designation.

Speaking during the same session, Richard Marsden, CEO of Southampton, U.K.-based Synairgen plc, identified a role for governments in tackling this problem. “If you’re just embarking on phase II trials now, you’re going to struggle to find sites and find patients,” he said. “A tricky thing that governments might have to do is kind of ration where drugs can get assessed in different trial sites.” The U.K. government is conferring urgent public health research status on select programs, which offers a kind of fast-lane to the most promising programs. Synairgen’s inhaled formulation of interferon-beta, SNG-001, recently received that designation. “Without it, you’d have to walk past the U.K., because you’re not going to get many people recruited into your clinical trial.” It’s a necessary intervention, given the urgent need to generate high-quality clinical data as quickly as possible. “Otherwise, everyone is going to end up with 50 or 60 patients in their trials, and we’ll all be scratching our heads trying to work out what worked and what didn’t work.”

————————